Quantcast

Latest Allos Therapeutics Inc. Stories

2014-02-13 16:27:51

--Hoffman to Increase PDL's Expertise in Biotech/Pharma Sector-- INCLINE VILLAGE, Nev., Feb. 13, 2014 /PRNewswire/ -- PDL BioPharma, Inc. (PDL) (NASDAQ: PDLI) today announced that the Company has retained Stephen J. Hoffman, M.D., Ph.D. as senior advisor to the Company, effective as of February 3, 2014. PDL is focused on acquiring income generating assets to continue increasing shareholder value. Dr. Hoffman brings more than 25 years of experience in biotech and pharma investing and...

2010-02-10 12:25:00

MINNETONKA, Minn., Feb. 10 /PRNewswire/ -- MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce that Allos Therapeutics' new international disease-specific registry for patients with peripheral T-cell lymphoma (PTCL) has enrolled its first study participant. This individual was enrolled Friday, February 5th by Dr. Haluk Tezcan at the Kootenia Cancer Center in Post Falls, ID. The registry, named...

2009-11-10 08:12:00

NCCN recently received a research grant from Allos Therapeutics, Inc. to evaluate the role of pralatrexate in the treatment of select hematologic malignancies and solid tumors. Pralatrexate is the only agent currently approved by the FDA to treat patients with relapsed or refractory peripheral T-cell lymphoma. Investigators from NCCN Member Institutions are eligible to apply for the research funding. FORT WASHINGTON, Pa., Nov. 10 /PRNewswire-USNewswire/ -- The National Comprehensive...

2008-11-05 18:00:22

Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the third quarter of 2008. For the three months ended September 30, 2008, the Company reported a net loss of $13.2 million, or ($0.16) per share. This compares to a net loss of $9.3 million, or ($0.14) per share, for the third quarter of 2007. For the nine months ended September 30, 2008, the Company reported a net loss of $37.0 million, or ($0.50) per share, compared to a net loss of $28.1 million, or ($0.43) per share, for...

2008-10-30 18:00:11

Allos Therapeutics, Inc. (Nasdaq: ALTH), a biopharmaceutical company focused on the development and commercialization of small molecule therapeutics for the treatment of cancer, today announced that four abstracts describing results from pralatrexate (PDX) studies have been accepted for presentation at the 50th Annual Meeting of the American Society of Hematology (ASH), to be held December 6 - 9, 2008, in San Francisco, California. The accepted abstracts describe several clinical and...

2008-08-05 18:00:40

Allos Therapeutics, Inc. (NASDAQ: ALTH) today reported results for the second quarter of 2008. For the three months ended June 30, 2008, the Company reported a net loss of $11.8 million, or ($0.16) per share. This compares to a net loss of $10.4 million, or ($0.16) per share, for the second quarter of 2007. For the six months ended June 30, 2008, the Company reported a net loss of $23.8 million, or ($0.34) per share, compared to a net loss of $18.8 million, or ($0.29) per share for the same...


Word of the Day
lunula
  • A small crescent-shaped structure or marking, especially the white area at the base of a fingernail that resembles a half-moon.
This word is a diminutive of the Latin 'luna,' moon.
Related